CD36 and congestive heart failure: Compared with the CHF model group, the ATP content in all drug administration groups was significantly increased (P < 0.001; Figure 11A); FFA levels in the captopril, UAS-H, SFAS-H, GCAS, and DGSAS groups were significantly decreased (P < 0.05 or P < 0.01; Figure 11B); CD36 expression levels were significantly increased in the captopril, UAS-H, UAS-L, SFAS-H, and GCAS groups (P < 0.05 or P < 0.01; Figures 11C,D); and CPT1 expression levels in the captopril, SFAS-H, GCAS, and DGSAS groups were significantly increased (P < 0.05 or P < 0.01; Figures 11E,F).